About Contact Us Careers
Sign In

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Trends

  • Report ID: 6740
  • Published Date: Nov 26, 2024
  • Report Format: PDF, PPT

Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market

  1. Introduction
    1. Study Objective
    2. Scope of the report
    3. Market Taxonomy
  2. Study Assumptions and Abbreviations
    1. Research Methodology
    2. Secondary Research
    3. Primary Research
    4. SPSS Approach
    5. Data Triangulation
  3. Executive Summary
  4. Global Industry Overview  
    1. Market Overview
    2. Regional Synopsis
    3. Industry Supply Chain Analysis
    4. DROT
      1. Driver
      2. Restraint
      3. Opportunities
      4. Trends
    5. Government Regulation: How they would Aid the Business?
    6. Competitive Landscape
      1. AstraZeneca PLC
      2. Eli Lilly & Company
      3. Galmed Pharmaceuticals Ltd.
      4. GENFIT S.A.
      5. Novo Nordisk A/S
      6. Novartis AG
      7. PFIZER INC.
      8. Siemens Healthineers AG
      9. TAKEDA PHARMACEUTICAL COMPANY LIMITED
      10. Zydus Lifesciences Limited
    7. SWOT Analysis
    8. Comparative Analysis Of The Current Technologies
    9. Company Share in The Market
    10. Analysis of Strategic Initiatives Adopted by Key Players
    11. Drug Type Analysis
    12. Growth Forecast of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
    13. Patent Analysis
    14. Recent Developments
    15. Industry Risk Assessment
  5. Global Outlook and Projections
    1. Global Overview
      1. Market Value (USD Million), Current and Future Projections, 2024-2037
      2. Increment $ Opportunity Assessment, 2024-2037
      3. Year-on-Year Growth Forecast (%)
    2. Global Segmentation (USD Million), 2024-2037, By
      1. Drug Type, Value (USD Million)
        1. Vitamin E and Pioglitazone
        2. Obeticholic Acid (OCA)
        3. Lanifibranor
        4. Semaglutide
        5. Resmetirom
        6. Aramchol
        7. Cenicriviroc
        8. Others
      2. End user, Value (USD Million)
        1. Hospital Pharmacies
        2. Retail and Specialty Pharmacies
        3. Others
    3. Regional Synopsis (USD Million), 2024-2037
      1. North America, Value (USD Million)
      2. Europe, Value (USD Million)
      3. Asia Pacific, Value (USD Million)
      4. Latin America, Value (USD Million)
      5. Middle East and Africa, Value (USD Million)
  6. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
  7. North America Market
    1. Overview
      1. Market Value (USD Million), Current and Future Projections, 2024-2037
      2. Increment $ Opportunity Assessment, 2024-2037
    2. Segmentation (USD Million), 2024-2037, By
      1. Drug Type, Value (USD Million)
        1. Vitamin E and Pioglitazone
        2. Obeticholic Acid (OCA)
        3. Lanifibranor
        4. Semaglutide
        5. Resmetirom
        6. Aramchol
        7. Cenicriviroc
        8. Others
      2. End user, Value (USD Million)
        1. Hospital Pharmacies
        2. Retail and Specialty Pharmacies
        3. Others
      3. Country Level Analysis, Value (USD Million)
        1. U.S.
        2. Canada
    3. Cross Analysis of Drug Type W.R.T. End user  (USD Million), 2024-2037
  8. Europe Market
    1. Overview
      1. Market Value (USD Million), Current and Future Projections, 2024-2037
      2. Increment $ Opportunity Assessment, 2024-2037
    2. Segmentation (USD Million), 2024-2037, By
      1. Drug Type, Value (USD Million)
        1. Vitamin E and Pioglitazone
        2. Obeticholic Acid (OCA)
        3. Lanifibranor
        4. Semaglutide
        5. Resmetirom
        6. Aramchol
        7. Cenicriviroc
        8. Others
      2. End user, Value (USD Million)
        1. Hospital Pharmacies
        2. Retail and Specialty Pharmacies
        3. Others
      3. Country Level Analysis, Value (USD Million)
        1. UK
        2. Germany
        3. France
        4. Italy
        5. Spain
        6. NORDIC
        7. Russia
        8. Rest of Europe
    3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
  9. Asia Pacific Market
    1. Overview
      1. Market Value (USD Million), Current and Future Projections, 2024-2037
      2. Increment $ Opportunity Assessment, 2024-2037
    2. Segmentation (USD Million), 2024-2037, By
      1. Drug Type, Value (USD Million)
        1. Vitamin E and Pioglitazone
        2. Obeticholic Acid (OCA)
        3. Lanifibranor
        4. Semaglutide
        5. Resmetirom
        6. Aramchol
        7. Cenicriviroc
        8. Others
      2. End user, Value (USD Million)
        1. Hospital Pharmacies
        2. Retail and Specialty Pharmacies
        3. Others
      3. Country Level Analysis, Value (USD Million)
        1. China
        2. Japan
        3. India
        4. Australia
        5. South Korea
        6. Vietnam
        7. Thailand
        8. Singapore
        9. Malaysia
        10. Rest of Asia Pacific
    3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
  10. Latin America Market
    1. Overview
      1. Market Value (USD Million), Current and Future Projections, 2024-2037
      2. Increment $ Opportunity Assessment, 2024-2037
    2. Segmentation (USD Million), 2024-2037, By
      1. Drug Type, Value (USD Million)
        1. Vitamin E and Pioglitazone
        2. Obeticholic Acid (OCA)
        3. Lanifibranor
        4. Semaglutide
        5. Resmetirom
        6. Aramchol
        7. Cenicriviroc
        8. Others
      2. End user, Value (USD Million)
        1. Hospital Pharmacies
        2. Retail and Specialty Pharmacies
        3. Others
      3. Country Level Analysis, Value (USD Million)
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
    3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
  11. Middle East & Africa Market
    1. Overview
      1. Market Value (USD Million), Current and Future Projections, 2024-2037
      2. Increment $ Opportunity Assessment, 2024-2037
    2. Segmentation (USD Million), 2024-2037, By
      1. Drug Type, Value (USD Million)
        1. Vitamin E and Pioglitazone
        2. Obeticholic Acid (OCA)
        3. Lanifibranor
        4. Semaglutide
        5. Resmetirom
        6. Aramchol
        7. Cenicriviroc
        8. Others
      2. End user, Value (USD Million)
        1. Hospital Pharmacies
        2. Retail and Specialty Pharmacies
        3. Others
      3. Country Level Analysis, Value (USD Million)
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
    3. Cross Analysis of Drug Type W.R.T. End user (USD Million), 2024-2037
  12. Global Economic Scenario
    1. World Economic Outlook
  13. About Research Nester
    1. Our Global Clientele
    2. We Serve Clients Across World

 

Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Trends

Growth Drivers

  • Increase in the prevalence of obesity and metabolic disorders: Unhealthy eating and sedentary living contribute to the rise in obesity and metabolic disorders that are increasing the cases of NASH. Furthermore, obesity and metabolic syndrome remain central among all the risk factors of fatty liver diseases, so there is an urgent need to enhance diagnostic and therapeutic solutions. Advanced tools are increasingly critical to better manage and monitor the conditions. In November 2023, Echosens received FDA clearance for a device known as FibroScan, a non-invasive test that measures stiffness and fat content in the liver. This technology enhances both early diagnosis and ongoing monitoring of patients with NASH, providing a safer alternative compared to the traditional approaches.
  • Improvement in diagnostics and non-invasive technologies: Non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market for better safety and convenience for patients. These innovations reduce the need for invasive procedures such as biopsies, making early detection more accessible. For example, in October 2023, Siemens Healthineers launched the Enhanced Liver Fibrosis (ELF) test. The diagnostic tool gives important insights into liver fibrosis that help in the better management of the disease. Such a development underlines the industry's commitment to enhancement in diagnostics by addressing comfort for the patient and efficiency of care.
  • Increased R&D investments in targeted therapies: Several pharmaceutical companies are accelerating efforts to develop targeted therapies for the treatment of NASH to respond appropriately to the increasing demand. This is also enabling newer approaches in patient care through substantial research and development investments. In January 2024, 89bio initiated a Phase III clinical trial with their promising drug candidate, specifically for the treatment of NASH. Such a strategic step in the competitive environment would help to realize patient-oriented solutions. Such focus on R&D will lead toward advancements that provide more accessible therapeutic options in the non-alcoholic steatohepatitis therapeutics and diagnostics market.

Challenges

  • Limited awareness and underdiagnosis: Despite its increasing prevalence, non-alcoholic steatohepatitis (NASH) remains significantly underdiagnosed, largely due to limited awareness among patients and healthcare providers. Many individuals with NASH remain asymptomatic until the disease progresses, delaying timely intervention. Additionally, the lack of standardized diagnostic tools contributes to the underdiagnosis, as invasive liver biopsies remain the primary method for confirmation.
  • Regulatory and clinical challenges: The development of effective therapies for NASH has various challenges due to complex regulatory pathways and the essentials of trials. Drug approval requires sound clinical data on safety and efficacy, which can only be achieved by large-volume, long-term studies. From the disease perspective, heterogeneity in NASH further makes it difficult to design a clinical trial because the different patient populations need to be considered and, in addition, at diverse stages of the disease. Another important barrier to developers is regulatory investigations into the side effects a given drug may have.

Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market: Key Insights

Base Year

2024

Forecast Year

2025-2037

CAGR

28.1%

Base Year Market Size (2024)

USD 4.6 billion

Forecast Year Market Size (2037)

USD 117 billion

Regional Scope

  • North America (U.S. and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF
Browse Key Market Insights with Data Illustration:

Author Credits:  Radhika Pawar


  • Report ID: 6740
  • Published Date: Nov 26, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In 2024, the industry size of non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics was USD 4.6 billion.

The global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market size was USD 4.6 billion in 2024 and is projected to reach USD 117 billion by the end of 2037, expanding at a CAGR of 28.1% during the forecast period, i.e., 2025-2037. In 2025, the industry size of non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics will be valued at USD 5.9 billion.

Key players in the market are AstraZeneca PLC, Eli Lilly & Company, Galmed Pharmaceuticals Ltd., Pfizer Inc., Genfit SA, Novo Nordisk A/S, Takeda Pharmaceutical Company Ltd., and Arcturus Therapeutics Inc among others.

The retail and specialty pharmacies segment is anticipated to lead the non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market during the forecast period.

North America is anticipated to offer lucrative prospects to companies in the non-alcoholic steatohepatitis (Nash) therapeutics and diagnostics market during the forecast period.
Inquiry Before Buying Request Free Sample

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample